TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/16/2026
Back to search
Official data from USPTO
EXO-TARGET
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
EXO-TARGET
ST13
US500000090357299Class
1, 5, 42
Filing
90357299
Registration
7637167
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
43
Latest update
03/18/2026
Trademark type
Word
Nice classes
1, 5, 42
Filing date
12/03/2020
Registration date
01/07/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/07/2025
Last transaction
03/18/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
03
Owner location
Daejeon, KR
Examiner
MCCLELLAN, MATTHEW D.
Law office
N30
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
ILIAS Biologics Inc.
Representatives
Janice Housey Litmus Law PLLC
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biological preparationsother than for medical or veterinary purposes; biological tissue culturesother than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; biological preparation for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of cosmetics; protein for use in the manufacture of cosmetics; proteins for the food industry; chemical reagentsother than for medical or veterinary purpose
Class 5
Pharmaceutical preparations for treating cancermetabolic diseaseinflammatory diseasegenetic diseaseinfectious diseasescardiovascular diseaserespiratory diseaseneurological diseaseauto-immune diseasefibrosis disease; chemico-pharmaceutical preparations for the treatment of cancermetabolic diseaseinflammatory diseasegenetic diseaseinfectious diseasescardiovascular diseaserespiratory diseaseneurological diseaseauto-immune diseasefibrosis disease; drug delivery agents in the form of capsulestabletspillspowdersliquidssuspensionsinjectioncreamsemulsionsgelslinimentslotionsointmentspathessolutionssyrupsaerosolsgranulesimplantsinhalantspellets that facilitate the delivery of pharmaceutical preparations for the treatment of cancermetabolic diseaseinflammatory diseasegenetic diseaseinfectious diseasescardiovascular diseaserespiratory diseaseneurological diseaseauto-immune diseasefibrosis disease; biological preparations in the nature of comprising extracellular vesicles known as exosomes for therapeutic applications; extracellular vesicles for pharmaceutical purposes for the treatment of cancermetabolic diseaseinflammatory diseasegenetic diseaseinfectious diseasescardiovascular diseaserespiratory diseaseneurological diseaseauto-immune diseasefibrosis disease; biochemical drug delivery agent in the form of capsulestabletspillspowdersliquidssuspensionsinjectioncreamsemulsionsgelslinimentslotionsointmentspathessolutionssyrupsaerosolsgranulesimplantsinhalantspellets that facilitate the delivery of pharmaceutical preparations for the treatment of cancermetabolic diseaseinflammatory diseasegenetic diseaseinfectious diseasescardiovascular diseaserespiratory diseaseneurological diseaseauto-immune diseasefibrosis disease; nutraceutical preparations for therapeutic or medical purposes for the treatment of cancermetabolic diseaseinflammatory diseasegenetic diseaseinfectious diseasescardiovascular diseaserespiratory diseaseneurological diseaseauto-immune diseasefibrosis disease; chemical preparations for pharmaceutical purposes for the treatment of cancermetabolic diseaseinflammatory diseasegenetic diseaseinfectious diseasescardiovascular diseaserespiratory diseaseneurological diseaseauto-immune diseasefibrosis disease; chemical preparations for medical purposes for the treatment of cancermetabolic diseaseinflammatory diseasegenetic diseaseinfectious diseasescardiovascular diseaserespiratory diseaseneurological diseaseauto-immune diseasefibrosis disease; preparations of microorganisms for medical and veterinary use for the treatment of cancermetabolic diseaseinflammatory diseasegenetic diseaseinfectious diseasescardiovascular diseaserespiratory diseaseneurological diseaseauto-immune diseasefibrosis disease; reagents for use in medical genetic testing; diagnostic reagents for medical use; biological preparations for medical or veterinary purposes for the treatment of cancermetabolic diseaseinflammatory diseasegenetic diseaseinfectious diseasescardiovascular diseaserespiratory diseaseneurological diseaseauto-immune diseasefibrosis disease; biological reagents for clinical medical use
Class 42
Biotechnology research; technological research in the field of cell biology; laboratory research in the field of cell biology; pharmaceutical drug development services; genetic testing for scientific research purposes; research in the field of chemistry; drug discovery services; medical research and development services; pharmaceutical research and development services; biopharmaceutical research and development services
Publications
History of USPTO decisions and trademark events.
43 publications found
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/16/2026
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
03/16/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/16/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/16/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/16/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/16/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/07/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
01/07/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/19/2024
PUBO
PUBLISHED FOR OPPOSITION
11/19/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/13/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/07/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/07/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
10/07/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
07/08/2024
GNFR
FINAL REFUSAL E-MAILED
07/08/2024
CNFR
FINAL REFUSAL WRITTEN
07/08/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/24/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/24/2024
ALIE
ASSIGNED TO LIE
06/24/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
05/26/2024
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
02/26/2024
GNSI
INQUIRY TO SUSPENSION E-MAILED
02/26/2024
CNSI
SUSPENSION INQUIRY WRITTEN
02/26/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
02/01/2024
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
07/06/2023
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
04/18/2023
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
10/12/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
07/18/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/05/2022
GNSL
LETTER OF SUSPENSION E-MAILED
01/05/2022
CNSL
SUSPENSION LETTER WRITTEN
01/05/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/04/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/03/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/03/2021
GNRT
NON-FINAL ACTION E-MAILED
06/03/2021
CNRT
NON-FINAL ACTION WRITTEN
06/03/2021
DOCK
ASSIGNED TO EXAMINER
05/20/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/09/2021
NWAP
NEW APPLICATION ENTERED
12/07/2020
Continuous trademark protection
Get notified about every new filing that threatens EXO-TARGET or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.